期刊文献+

造血干细胞移植预处理诱发口腔黏膜炎模型的建立 被引量:1

Establishment of an animal model of oral mucositis induced by conditioning regimen of haematopoietic stem cell transplantation
原文传递
导出
摘要 目的探讨建立造血干细胞移植预处理诱发口腔黏膜炎大鼠模型的可行性。方法采用马利兰和环磷酰胺预处理方案结合左颊黏膜搔刮建立大鼠口腔黏膜炎模型。设立模型组和对照组,从自然过程、口腔黏膜炎指数、血象、骨髓象、病理检查等指标动态观察口腔黏膜炎的发生、发展过程。结果模型组大鼠于第7天开始出现口腔黏膜炎表现,发生率为80.00%;口腔黏膜炎指数在第11天达到峰值(2.04±1.80),4级以上口腔黏膜炎占39.29%(11/28);第18~21天病损基本恢复,期间大鼠体重持续下降,白细胞计数于第10天下降至最低点,骨髓增生度低下。结论成功建立了造血干细胞移植预处理诱发口腔黏膜炎的大鼠模型。 Objective To establish a rat model of oral mucositis (OM) induced by busulfan and cyclophosphamide (BUCY) conditioning regimen of hematopoietic stem cell transplantation (HSCT). Methods In the model group, busulfan (6. 0 mg · kg^-1 · d^-1× 4 d) and cyclophosphamide (120 mg · kg^-1 · d^-1× 2 d) were administered by intrastomach perfusion and intraperitoneal injection, respectively. The left cheek mucosas were irritated by superficial scratching on day 6. The oral mucosal score (OMS) was assessed daily. Animals were sacrificed on day 7, 10, 13, 16 and 18. The samples of blood, bone marrow, and the oral mucosa were harvest to evaluate the clinical and histological changes. Results The incidence of oral mucositis in model group was as high as 80. 00% with a survival rate of 73.33%. The initial lesion on the oral mucosa was noted on day 7 with red spot and edema, and then progressive mucositis was characterized by large areas of ulcer formation. The duration of oral mucositis was 8 to 10 days. A continuous weight loss, white blood cell count decrease and bone marrow suppression occurred in the process of oral mucositis. Conclusions An animal model of conditioning regimen-induced oral mucositis was successfully established.
出处 《中华口腔医学杂志》 CAS CSCD 北大核心 2007年第11期672-676,共5页 Chinese Journal of Stomatology
基金 广东省科技计划项目(2005850301004 2006836006014)
关键词 造血干细胞移植 移植预处理 口腔黏膜 白消安 环磷酰胺 Hematopoietic stem cell transplantation Transplantation conditioning Mouth mucosa Busulfan Cyclophosphamide
  • 相关文献

参考文献12

  • 1Sonis ST, Tracey C, Shklar G, et al. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol, 1990, 69 (4) : 437-443.
  • 2Dorr W, Spekl K , Martin M. Radiation-induced oral mucositis in mice : strain differences. Cell Prolif, 2002, 35 Suppl 1:60-67.
  • 3Sonis ST, O' Donnell KE, Popat R, et al. The relationship between mucosal cydooxygenase-2 ( COX-2 ) expression and experimental radiation-induced mucositis. Oral Oncology, 2004, 40(2) : 170-176.
  • 4童秀珍,李娟,谭恩勋,张国材,吴祥元,彭爱华,郑冬,邹外一,洪文德,罗绍凯.HLA相合同胞供者异基因造血干细胞移植治疗慢性粒细胞白血病的疗效及预后因素分析[J].中华肿瘤杂志,2006,28(7):545-548. 被引量:5
  • 5Lima V, Brito GA, Cunha FQ, et al. Effects of the tumour necrosisi factor-alpha inhibitors pentoxigylline and thalidomide in short-term experimental oral mucositis in hamsters. Eur J Oral Sci, 2005, 113(3) : 210-217.
  • 6Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy- induced oral and gastrointestinal mucositis. Cancer, 2004, 100(9 Suppl) : 2026-2046.
  • 7朱康儿,徐旸,吴东,许晓华,黄连生.异基因外周血造血干细胞移植马利兰和环磷酰胺预处理的不良反应研究[J].中华血液学杂志,2000,21(8):403-405. 被引量:6
  • 8Gabriel DA, Shea T, Olajida O, et al. The effect of oral mucositis on morbidity and mortality in bone marrow transplant. Semin Oncol, 2003, 30(6 Suppl 18): 76-83.
  • 9Barasch A, Peterson DE, Tanzer JM. Helium-neon laser effects conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer, 1995,76( 12 ) : 2250-2256.
  • 10Sonis ST, Peterson RL, Edwards LJ, et al. Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol, 2000, 36(4) : 373-381.

二级参考文献11

  • 1Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med, 2002, 346: 645-652.
  • 2Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol, 2003, 40: 59-71.
  • 3Koh LP, Hwang WY, Tan CH, et al. Long term follow-up of Asian patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling: evaluation of risks and benefits. Ann Hematol, 2004, 83:286-294.
  • 4Kanda Y, Chiba S, Hirai H, et al. Allogenic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood, 2003, 102:1541-1547.
  • 5Socie G, Clift RA, Blaise D, et al. Busulfan plus eyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood, 2001, 98:3569-3574.
  • 6Qazilbash MH, Devetten MP, Abraham J, et al. Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia. Aeta Haematol, 2003, 109:119-123.
  • 7Copelan EA, Penza SL, Theil KS, et al. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy.Bone Marrow Transplant, 2000, 26: 1037-1043.
  • 8Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.Blood, 2002, 99: 1971-1977.
  • 9马恩普,韩颖.异基因外周血干细胞移植中的GVHD比骨髓移植更严重吗?[J].临床血液学杂志,1998,11(3):137-140. 被引量:6
  • 10曹履先.骨髓移植与恶性肿瘤[J].中华肿瘤杂志,2000,22(5):357-358. 被引量:1

共引文献9

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部